Driehaus Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$232M	Buy	6,395,922 +8,182	+0.1%	+$365K	1.71%	4
2025 Q4	$297M	Sell	6,387,740 -93,873	-1%	-$4.18M	2.02%	2
2025 Q3	$270M	Buy	6,481,613 +81,588	+1%	+$2.61M	1.93%	2
2025 Q2	$184M	Buy	6,400,025 +160,123	+3%	+$4.94M	1.47%	6
2025 Q1	$209M	Buy	6,239,902 +98,888	+2%	+$3.69M	2.02%	3
2024 Q4	$314M	Buy	6,141,014 +255,766	+4%	+$14.3M	2.59%	2
2024 Q3	$301M	Sell	5,885,248 -226,925	-4%	-$11.7M	2.58%	2
2024 Q2	$274M	Buy	6,112,173 +885,876	+17%	+$40.9M	2.65%	2
2024 Q1	$245M	Buy	5,226,297 +186,340	+4%	+$7.29M	2.44%	3
2023 Q4	$179M	Sell	5,039,957 -92,330	-2%	-$2.83M	2.16%	3
2023 Q3	$153M	Sell	5,132,287 -165,801	-3%	-$3.42M	1.98%	4
2023 Q2	$95.5M	Buy	5,298,088 +8,569	+0.2%	+$171K	1.21%	11
2023 Q1	$84.9M	Sell	5,289,519 -335,225	-6%	-$6.2M	1.19%	7
2022 Q4	$103M	Sell	5,624,744 -7,214	-0.1%	-$127K	1.53%	5
2022 Q3	$111M	Buy	5,631,958 +157,499	+3%	+$3.21M	1.67%	4
2022 Q2	$102M	Buy	5,474,459 +530,446	+11%	+$10.6M	1.65%	4
2022 Q1	$109M	Buy	4,944,013 +150,375	+3%	+$3.04M	1.33%	5
2021 Q4	$136M	Buy	4,793,638 +1,795,126	+60%	+$44.3M	1.39%	4
2021 Q3	$63.1M	Buy	2,998,512 +290,687	+11%	+$6.08M	0.75%	32
2021 Q2	$51M	Buy	2,707,825 +704,137	+35%	+$12.4M	0.68%	31
2021 Q1	$30.6M	Buy	2,003,688 +549,722	+38%	+$8.52M	0.45%	59
2020 Q4	$20.5M	Buy	1,453,966 +579,124	+66%	+$8.07M	0.33%	96
2020 Q3	$13.7M	Sell	874,842 -11,920	-1%	-$182K	0.28%	102
2020 Q2	$15.5M	Buy	+886,762	New	+$15.1M	0.38%	79